Romero J, Berrendero F, García-Gil L, Lin S Y, Makriyannis A, Ramos J A, Fernández-Ruiz J J
Instituto Complutense de Drogodependencias, Department of Biochemistry, Faculty of Medicine, Complutense University, Madrid, Spain.
Neurochem Int. 1999 Jun;34(6):473-82. doi: 10.1016/s0197-0186(99)00020-0.
We and others have recently demonstrated that the pharmacological tolerance observed after prolonged exposure to plant and synthetic cannabinoids in adult individuals seems to have a pharmacodynamic basis, based on the observed down-regulation of cannabinoid receptors in the brain of cannabinoid-tolerant rats. However, we were unable to elicit a similar receptor down-regulation after a chronic exposure to anandamide, the first discovered endogenous cannabinoid, possibly because of its rapid metabolic breakdown in arachidonic acid and ethanolamine. The present study was designed to progress in these previous studies, by using R-methanandamide, a more stable analog, instead anandamide. In addition, we examined not only cannabinoid receptor binding, but also WIN-55,212-2-stimulated [35S]-GTPgammaS binding, by autoradiography, and cannabinoid receptor mRNA levels, by in situ hybridization. Results were as follows. The daily administration of R-methanandamide for a period of five days produced decreases in cannabinoid receptor binding in the lateral caudate-putamen, cerebellum, entopeduncular nucleus and substantia nigra. The remaining areas, the medial caudate-putamen, globus pallidus, cerebral cortex (layers I and VI), hippocampus (dentate gyrus and Ammon's horn) and several limbic structures (nucleus accumbens, septum nuclei and basolateral amygdaloid nucleus), exhibited no changes in cannabinoid receptor binding. Similarly, the levels of cannabinoid receptor mRNA expression decreased in the lateral and medial caudate-putamen and in the CA1 and CA2 subfields of the Ammon's horn in the hippocampus after the chronic exposure to R-methanandamide, whereas the remaining areas showed no changes. WIN-55,212-2-stimulated [35S]-GTPgammaS binding did not change in the lateral caudate-putamen, cerebral cortex (layer I), septum nuclei and hippocampal structures (dentate gyrus and Ammon's horn) of animals chronically exposed to R-methanandamide, whereas a certain trend to decrease could be observed in the substantia nigra and deep layer (VI) of the cerebral cortex in these animals. In summary, as reported for other cannabinoid receptor agonists, the prolonged exposure of rats to R-methanandamide, a more stable analog of anandamide, was able to produce cannabinoid receptor-related changes in contrast with the absence of changes observed early with the metabolically labile anandamide. The observed changes exhibited an evident regional pattern with areas, such as basal ganglia, cerebellum and hippocampus, responding to chronic R-methanandamide treatment while regions, such as the cerebral cortex and limbic nuclei, not responding.
我们和其他研究人员最近证明,在成年个体中长期接触植物性和合成大麻素后观察到的药理学耐受性似乎具有药效学基础,这是基于在大麻素耐受性大鼠大脑中观察到的大麻素受体下调。然而,在长期接触首个被发现的内源性大麻素——花生四烯乙醇胺后,我们未能引发类似的受体下调,这可能是因为它在花生四烯酸和乙醇胺中快速代谢分解。本研究旨在通过使用更稳定的类似物R-甲烷花生四烯酸乙醇胺而非花生四烯乙醇胺,在前述研究基础上取得进展。此外,我们不仅通过放射自显影检查了大麻素受体结合情况,还检查了WIN-55,212-2刺激的[35S]-GTPγS结合情况,并通过原位杂交检查了大麻素受体mRNA水平。结果如下。连续五天每日给予R-甲烷花生四烯酸乙醇胺,导致外侧尾状核-壳核、小脑、内苍白球核和黑质中的大麻素受体结合减少。其余区域,即内侧尾状核-壳核、苍白球、大脑皮层(I层和VI层)、海马体(齿状回和海马角)以及几个边缘结构(伏隔核、隔核和基底外侧杏仁核),大麻素受体结合未发生变化。同样,在长期接触R-甲烷花生四烯酸乙醇胺后,外侧和内侧尾状核-壳核以及海马体海马角的CA1和CA2亚区中的大麻素受体mRNA表达水平降低,而其余区域未显示变化。在长期接触R-甲烷花生四烯酸乙醇胺的动物中,外侧尾状核-壳核、大脑皮层(I层)、隔核和海马结构(齿状回和海马角)中WIN-55,212-2刺激的[35S]-GTPγS结合没有变化,而在这些动物的黑质和大脑皮层深层(VI层)中可观察到一定的下降趋势。总之,正如其他大麻素受体激动剂的报道一样,与代谢不稳定的花生四烯乙醇胺早期观察到的无变化情况相比,大鼠长期接触更稳定的类似物R-甲烷花生四烯酸乙醇胺能够产生与大麻素受体相关的变化。观察到的变化呈现出明显的区域模式,基底神经节、小脑和海马体等区域对慢性R-甲烷花生四烯酸乙醇胺治疗有反应,而大脑皮层和边缘核等区域则无反应。